

Highlights of This Issue 731

SMALL MOLECULE THERAPEUTICS

733 TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, and Kenichi Matsuo

743 Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model

Mandy Berndt-Paetz, Philipp Schulze, Philipp C. Stenglein, Annett Weimann, Qiang Wang, Lars-Christian Horn, Yasser M. Riyad, Jan Griebel, Ralf Hermann, Annegret Glasow, Jens-Uwe Stolzenburg, and Jochen Neuhaus

751 Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer

Bo Ram Kim, Yoon A. Jeong, Min Jee Jo, Seong Hye Park, Yoo Jin Na, Jung Lim Kim, Soyeon Jeong, Hye Kyeong Yun, Sanghee Kang, Dae-Hee Lee, and Sang Cheul Oh

762 Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin

Remco Nagel, Ana Teresa Avelar, Nanne Aben, Natalie Proost, Marieke van de Ven, Jan van der Vliet, Miranda Cozijnsen, Hilda de Vries, Lodewyk F. A. Wessels, and Anton Berns

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

771 Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Jennifer L. Green, Eric S. Okerberg, Josilyn Sejd, Marta Palafox, Laia Monserrat, Senait Alemayehu, Jiangyue Wu, Maria Sykes, Arwin Aban, Violeta Serra, and Tyzoon Nomanbhoy

780 Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction

Fu Li, Michelle L. Ulrich, Vincent Feng-Sheng Shih, Julia H. Cochran, Joshua H. Hunter, Lori Westendorf, Jason Neale, and Dennis R. Benjamin

788 CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma

Gargi Maity, Arnab Ghosh, Vijayalaxmi Gupta, Inamul Haque, Sandipto Sarkar, Amlan Das, Kakali Dhar, Sneha Bhavanasi, Sumedha S. Gunewardena, Daniel D. Von Hoff, Sanku Mallik, Suman Kambhampati, Sushanta K. Banerjee, and Snigdha Banerjee

801 β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer

Georgios Kallifatidis, Diandra K. Smith, Daley S. Morera, Jie Gao, Martin J. Hennig, James J. Hoy, Richard F. Pearce, Isha R. Dabke, Jiemin Li, Axel S. Merseburger, Markus A. Kuczyk, Vinata B. Lokeshwar, and Bal L. Lokeshwar

812 δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion

Toshihiko Shimizu, Joji Ishida, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Yoshihiro Otani, Tetsuo Oka, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, and Isao Date

823 Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies

Joseph Tintelnot, Natalie Baum, Christoph Schultheiß, Friederike Braig, Marie Trentmann, Johannes Finter, William Fumey, Peter Bannas, Boris Fehse, Kristoffer Riecken, Kerstin Schuetze, Carsten Bokemeyer, Thies Rösner, Thomas Valerius, Matthias Peipp, Friedrich Koch-Nolte, and Mascha Binder

834 Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma

Marcel Trautmann, Magdalene Cyra, Ilka Isfort, Birte Jeiler, Arne Krüger, Inga Grünwald, Konrad Steinestel, Bianca Altwater, Claudia Rossig, Susanne Hafner, Thomas Simmet, Jessica Becker, Pierre Åman, Eva Wardelmann, Sebastian Huss, and Wolfgang Hartmann

Table of Contents

845 EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer



Giulia Martini, Claudia Cardone, Pietro Paolo Vitiello, Valentina Belli, Stefania Napolitano, Teresa Troiani, Davide Ciardiello, Carminia Maria Della Corte, Floriana Morgillo, Nunzia Matrone, Vincenzo Sforza, Gianpaolo Papaccio, Vincenzo Desiderio, Mariel C. Paul, Veronica Moreno-Viedma, Nicola Normanno, Anna Maria Rachiglio, Virginia Tirino, Evaristo Maiello, Tiziana Pia Latiano, Daniele Rizzi, Giuseppe Signoriello, Maria Sibilia, Fortunato Ciardiello, and Erika Martinelli

856 Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition

Anthony S. Fischl, Xiaoen Wang, Beverly L. Falcon, Rowena Almonte-Baldonado, Diane Bodenmiller, Glenn Evans, Julie Stewart, Takako Wilson, Philip Hipskind, Jason Manro, Mark T. Uhlik, Sudhakar Chintharlapalli, Damien Gerald, David C. Alsop, Laura E. Benjamin, and Rupal S. Bhatt



AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

CORRECTION

868 Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer

Toni M. Brand, Mari Iida, Emily F. Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David Yang, Kari B. Wisinski, Ravi Salgia, and Deric L. Wheeler


RETRACTION

869 Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro, and Ching-Shih Chen

ABOUT THE COVER

Currently, the recommended therapy for muscle-invasive urothelial cancer includes radical cystectomy with or without chemotherapy. In an attempt to develop an organ-sparing therapy, Berndt-Paetz and colleagues demonstrate the use of photodynamic therapy (PDT) in an orthotopic rat model. PDT with the near-infrared photosensitizer Tetrahydroporphyrin-Tetratosylat generated inflammation (at center) in the urothelial tumor (top right corner) without damaging the surrounding urothelium (lower left), submucosal tissue (lower left), or bladder smooth muscle (upper left). Their results suggest PDT is worthy of clinical consideration in muscle-invasive urothelial cancer.



Molecular Cancer Therapeutics

18 (4)

Mol Cancer Ther 2019;18:731-869.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/4>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.